Knowledge is power when living with prostate cancer.
Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.Already a subscriber? Sign in here
Sophiris to Begin Dosing Patients in Phase 2b Study of Topsalysin for Prostate Cancer
Sophiris Bio has received a green light to begin dosing patients in a Phase 2b U.S. clinical trial of topsalysin (PRX302) for prostate cancer. The go-ahead was in the form of a Federal Drug Administration approval of a substance that Sophiris uses to dilute topsalysin, according to a press release. The therapy is for an enlarged prostate as well